These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28516744)

  • 41. Regional Features of MuSK Antibody-Positive Myasthenia Gravis in Northeast China.
    Zhang Z; Guan Y; Han J; Li M; Shi M; Deng H
    Front Neurol; 2020; 11():516211. PubMed ID: 33123066
    [No Abstract]   [Full Text] [Related]  

  • 42. Seronegative myasthenia gravis: comparison of neurophysiological picture in MuSK+ and MuSK- patients.
    Padua L; Tonali P; Aprile I; Caliandro P; Bartoccioni E; Evoli A
    Eur J Neurol; 2006 Mar; 13(3):273-6. PubMed ID: 16618345
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myopathy, muscle atrophy and tongue lipid composition in MuSK myasthenia gravis.
    Nikolić AV; Bačić GG; Daković MŽ; Lavrnić SĐ; Rakočević Stojanović VM; Basta IZ; Lavrnić DV
    Acta Neurol Belg; 2015 Sep; 115(3):361-5. PubMed ID: 25253293
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Palpebral portion of the orbicularis oculi muscle to repetitive nerve stimulation testing: A potential assessment indicator in patients with generalized myasthenia gravis.
    Yan C; Song J; Pang S; Yi F; Xi J; Zhou L; Ding D; Wang W; Qiao K; Zhao C
    J Clin Neurosci; 2018 Feb; 48():238-242. PubMed ID: 29239825
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis.
    Vincent A; Leite MI
    Curr Opin Neurol; 2005 Oct; 18(5):519-25. PubMed ID: 16155434
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Is paravertebral muscles edema a consequence of neurogenic changes in MuSK-positive myasthenia gravis?
    Bardakov SN; Tsargush VA; Carlier PG; Duc TM; Emelin AY; Polushin AY; Emelyantsev AA; Belskikh AN; Berezhnaya EN; Lapin SV; Moshnikova AN; Deev RV
    Acta Myol; 2022; 41(4):178-187. PubMed ID: 36793652
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-MuSK myasthenia gravis with prolonged remission.
    Bouwyn JP; Magnier P; Bédat-Millet AL; Ahtoy P; Maltête D; Lefaucheur R
    Neuromuscul Disord; 2016 Jul; 26(7):453-4. PubMed ID: 27161384
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Muscle-Specific Kinase Myasthenia Gravis.
    Borges LS; Richman DP
    Front Immunol; 2020; 11():707. PubMed ID: 32457737
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Ocular involvement in MuSK antibody-positive myasthenia gravis].
    Bau V; Hanisch F; Hain B; Zierz S
    Klin Monbl Augenheilkd; 2006 Jan; 223(1):81-3. PubMed ID: 16418940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics Of acetylcholine-receptor-antibody-negative myasthenia gravis in a South African cohort.
    Huda S; Woodhall MR; Vincent A; Heckmann JM
    Muscle Nerve; 2016 Dec; 54(6):1023-1029. PubMed ID: 27105303
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decremental response of the nasalis and hypothenar muscles in myasthenia gravis.
    Niks EH; Badrising UA; Verschuuren JJ; Van Dijk JG
    Muscle Nerve; 2003 Aug; 28(2):236-8. PubMed ID: 12872330
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Are MuSK antibodies the primary cause of myasthenic symptoms?
    Selcen D; Fukuda T; Shen XM; Engel AG
    Neurology; 2004 Jun; 62(11):1945-50. PubMed ID: 15184594
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Myopathic changes detected by quantitative electromyography in patients with MuSK and AChR positive myasthenia gravis.
    Nikolic A; Basta I; Stojanovic VR; Stevic Z; Peric S; Lavrnic D
    J Clin Neurosci; 2016 May; 27():126-9. PubMed ID: 26778359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis.
    Zisimopoulou P; Evangelakou P; Tzartos J; Lazaridis K; Zouvelou V; Mantegazza R; Antozzi C; Andreetta F; Evoli A; Deymeer F; Saruhan-Direskeneli G; Durmus H; Brenner T; Vaknin A; Berrih-Aknin S; Frenkian Cuvelier M; Stojkovic T; DeBaets M; Losen M; Martinez-Martinez P; Kleopa KA; Zamba-Papanicolaou E; Kyriakides T; Kostera-Pruszczyk A; Szczudlik P; Szyluk B; Lavrnic D; Basta I; Peric S; Tallaksen C; Maniaol A; Tzartos SJ
    J Autoimmun; 2014 Aug; 52():139-45. PubMed ID: 24373505
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New strategy for improving the diagnostic sensitivity of repetitive nerve stimulation in myasthenia gravis.
    Bou Ali H; Salort-Campana E; Grapperon AM; Gallard J; Franques J; Sevy A; Delmont E; Verschueren A; Pouget J; Attarian S
    Muscle Nerve; 2017 Apr; 55(4):532-538. PubMed ID: 27511866
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes.
    Kefalopoulou ZM; Veltsista D; Germeni A; Lykouras D; Tsiamaki E; Chroni E
    Neurol Sci; 2024 Mar; 45(3):1233-1242. PubMed ID: 37831214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negative myasthenia gravis.
    Pevzner A; Schoser B; Peters K; Cosma NC; Karakatsani A; Schalke B; Melms A; Kröger S
    J Neurol; 2012 Mar; 259(3):427-35. PubMed ID: 21814823
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical value of cell-based assays in the characterisation of seronegative myasthenia gravis.
    Damato V; Spagni G; Monte G; Woodhall M; Jacobson L; Falso S; Smith T; Iorio R; Waters P; Irani SR; Vincent A; Evoli A
    J Neurol Neurosurg Psychiatry; 2022 Sep; 93(9):995-1000. PubMed ID: 35835469
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis.
    Nikolic A; Djukic P; Basta I; Hajdukovic Lj; Stojanovic VR; Stevic Z; Nikolic D; Bozic V; Lavrnic S; Lavrnic D
    Clin Neurol Neurosurg; 2013 Apr; 115(4):432-7. PubMed ID: 22770539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.